ROCKVILLE, Md., May 20, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will present an overview of the Company at the following investor conferences in May and June 2013:
|Deutche Bank Conference:|
|Presentation Date: Thursday, May 30th|
|Time: 2:50 PM ET|
|Place: The Westin Boston Waterfront Hotel- Boston, MA|
|Presentation Date: Tuesday, June 4th|
|Time: 10:00 AM ET|
|Place: Grand Hyatt New York- New York, NY|
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has one approved product for epilepsy, Oxtellar XR TM (extended release oxcarbazepine), and one tentatively approved product for epilepsy, Trokendi XR TM (extended release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591